Product Code: ETC13281729 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Advanced Therapy Medicinal Products CDMO Market was valued at USD 4.2 Billion in 2024 and is expected to reach USD 7.9 Billion by 2031, growing at a compound annual growth rate of 7.60% during the forecast period (2025-2031).
The Global Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) market is experiencing rapid growth driven by the increasing adoption of advanced therapies such as gene therapy, cell therapy, and tissue engineering. These therapies offer promising treatment options for a range of diseases, leading to a surge in demand for specialized manufacturing services. Key players in the market are expanding their capabilities to meet the complex manufacturing requirements of advanced therapies, including viral vector production and cell processing. The market is characterized by collaborations between biopharmaceutical companies and CDMOs to leverage expertise and resources, as well as strategic investments in facility expansions and technology upgrades. As regulatory agencies provide more clarity and support for advanced therapies, the CDMO market is expected to continue its growth trajectory in the coming years.
The Global Advanced Therapy Medicinal Products CDMO market is experiencing significant growth driven by the increasing demand for innovative cell and gene therapies. Key trends include a rise in outsourcing of manufacturing and development services by biotech and pharmaceutical companies to CDMOs, as well as the expansion of CDMOs` capabilities to meet the complex requirements of advanced therapies. Opportunities in the market include strategic partnerships and collaborations between CDMOs and therapy developers, technological advancements in manufacturing processes, and geographical expansion to tap into emerging markets. Additionally, the increasing regulatory support and funding for advanced therapies further boost the market`s growth potential. Overall, the Global Advanced Therapy Medicinal Products CDMO market presents promising prospects for players looking to capitalize on the expanding landscape of advanced therapies.
The Global Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) market faces several challenges, including regulatory complexities, high manufacturing costs, and the need for specialized expertise. The stringent regulatory requirements for advanced therapy products can create barriers to market entry and delay product commercialization. Additionally, the high cost of manufacturing these personalized therapies, such as gene and cell therapies, poses a financial challenge for both CDMOs and therapy developers. Furthermore, the specialized nature of advanced therapy manufacturing necessitates a high level of expertise and infrastructure, leading to limited availability of skilled personnel and facilities. Addressing these challenges will be crucial for the continued growth and success of the Global Advanced Therapy Medicinal Products CDMO market.
The Global Advanced Therapy Medicinal Products CDMO Market is primarily driven by the increasing adoption of advanced therapies for the treatment of various diseases, such as cancer, genetic disorders, and autoimmune diseases. The growing demand for personalized medicine and the promising results of advanced therapy medicinal products (ATMPs) in clinical trials are also fueling market growth. Additionally, the rising investments in research and development activities, along with the expanding pipeline of ATMPs, are driving the need for contract development and manufacturing organizations (CDMOs) specialized in advanced therapies. Furthermore, the complexities involved in manufacturing ATMPs and the requirement for specialized expertise and infrastructure are driving pharmaceutical and biotechnology companies to outsource these services to CDMOs, thus boosting the market for ATMP CDMOs.
Government policies related to the Global Advanced Therapy Medicinal Products CDMO Market vary by country and region. In general, regulatory bodies such as the FDA in the US and the EMA in Europe have established guidelines and requirements for the development, manufacturing, and commercialization of advanced therapy medicinal products (ATMPs) through contract development and manufacturing organizations (CDMOs). These policies aim to ensure product safety, efficacy, and quality standards are met, while also promoting innovation and access to advanced therapies. Additionally, governments may offer incentives or funding support to encourage the growth of the ATMP CDMO market, as these therapies hold promise for treating various diseases and improving patient outcomes. Overall, adherence to regulatory frameworks and alignment with government priorities are essential for CDMOs operating in this dynamic and evolving market landscape.
The Global Advanced Therapy Medicinal Products (ATMP) Contract Development and Manufacturing Organization (CDMO) Market is poised for significant growth in the coming years. With the increasing prevalence of complex diseases and the rise of personalized medicine, there is a growing demand for advanced therapies such as gene therapies, cell therapies, and tissue engineering. ATMP CDMOs play a crucial role in providing specialized manufacturing and development services to biopharmaceutical companies looking to bring these innovative therapies to market. Factors such as technological advancements, favorable regulatory environment, and strategic collaborations are expected to drive the expansion of the ATMP CDMO market globally. As the adoption of advanced therapies continues to rise, the ATMP CDMO market is forecasted to experience substantial growth and offer lucrative opportunities for market players in the foreseeable future.
The Global Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth across regions. In Asia, particularly in countries like Japan and South Korea, there is a growing presence of CDMOs specializing in advanced therapies. North America remains a key market due to strong investment in biopharmaceuticals and advanced therapies. Europe is a hub for ATMP manufacturing with established CDMOs in countries like Germany and the UK. In the Middle East and Africa region, there is a rising interest in developing capabilities for advanced therapies, presenting opportunities for CDMOs. Latin America is also witnessing growth in the ATMP CDMO market, driven by increasing investments in biotechnology and healthcare infrastructure. Overall, each region offers unique opportunities and challenges for CDMOs operating in the advanced therapy medicinal products market.
Global Advanced Therapy Medicinal Products CDMO Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Advanced Therapy Medicinal Products CDMO Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Global Advanced Therapy Medicinal Products CDMO Market - Industry Life Cycle |
3.4 Global Advanced Therapy Medicinal Products CDMO Market - Porter's Five Forces |
3.5 Global Advanced Therapy Medicinal Products CDMO Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Advanced Therapy Medicinal Products CDMO Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Global Advanced Therapy Medicinal Products CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.8 Global Advanced Therapy Medicinal Products CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Global Advanced Therapy Medicinal Products CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Advanced Therapy Medicinal Products CDMO Market Trends |
6 Global Advanced Therapy Medicinal Products CDMO Market, 2021 - 2031 |
6.1 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Gene Therapy, 2021 - 2031 |
6.1.3 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Cell Therapy, 2021 - 2031 |
6.1.4 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Tissue-Engineered Products, 2021 - 2031 |
6.2 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Manufacturing, 2021 - 2031 |
6.2.3 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Research & Development, 2021 - 2031 |
6.2.4 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031 |
6.3.3 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Biotechnology Companies, 2021 - 2031 |
6.3.4 Global Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Hospitals & Clinics, 2021 - 2031 |
7 North America Advanced Therapy Medicinal Products CDMO Market, Overview & Analysis |
7.1 North America Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 - 2031 |
7.2 North America Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
7.4 North America Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
7.5 North America Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Latin America (LATAM) Advanced Therapy Medicinal Products CDMO Market, Overview & Analysis |
8.1 Latin America (LATAM) Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
8.4 Latin America (LATAM) Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
8.5 Latin America (LATAM) Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
9 Asia Advanced Therapy Medicinal Products CDMO Market, Overview & Analysis |
9.1 Asia Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
9.4 Asia Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
9.5 Asia Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
10 Africa Advanced Therapy Medicinal Products CDMO Market, Overview & Analysis |
10.1 Africa Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
10.4 Africa Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
10.5 Africa Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
11 Europe Advanced Therapy Medicinal Products CDMO Market, Overview & Analysis |
11.1 Europe Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
11.4 Europe Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
11.5 Europe Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
12 Middle East Advanced Therapy Medicinal Products CDMO Market, Overview & Analysis |
12.1 Middle East Advanced Therapy Medicinal Products CDMO Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
12.4 Middle East Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By Service, 2021 - 2031 |
12.5 Middle East Advanced Therapy Medicinal Products CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
13 Global Advanced Therapy Medicinal Products CDMO Market Key Performance Indicators |
14 Global Advanced Therapy Medicinal Products CDMO Market - Export/Import By Countries Assessment |
15 Global Advanced Therapy Medicinal Products CDMO Market - Opportunity Assessment |
15.1 Global Advanced Therapy Medicinal Products CDMO Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Advanced Therapy Medicinal Products CDMO Market Opportunity Assessment, By Product Type, 2021 & 2031F |
15.3 Global Advanced Therapy Medicinal Products CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
15.4 Global Advanced Therapy Medicinal Products CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
16 Global Advanced Therapy Medicinal Products CDMO Market - Competitive Landscape |
16.1 Global Advanced Therapy Medicinal Products CDMO Market Revenue Share, By Companies, 2024 |
16.2 Global Advanced Therapy Medicinal Products CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |